Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation

Pavani Chalasani, Sandra Kurtin, Tomislav Dragovich

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Context: Gemcitabine remains the mainstay of palliative chemotherapy for those patients with unresectable or metastatic pancreatic cancer. Objective radiological responses to gemcitabine are rare and reported median survival is only about six months. New therapeutic concepts and strategies are needed in order to improve those dismal statistics. Case report: We report here a case of a patient with metastatic pancreatic cancer responding to a third-line therapy with combination of mitomycin C and capecitabine. Interestingly, the patient had a strong family history of breast cancer and tested positive to germline BRCA2 mutation. Conclusion: We feel that this is of interest because of preclinical reports of increased sensitivity of pancreatic cells carrying BRCA2 mutations to DNA-intercalating agents such as mitomycin C. Further research and clinical trials are warranted to support this novel concept.

Original languageEnglish (US)
Pages (from-to)305-308
Number of pages4
JournalJournal of the Pancreas
Volume9
Issue number3
StatePublished - May 2008

Fingerprint

gemcitabine
Germ-Line Mutation
Mitomycin
Adenocarcinoma
Pancreatic Neoplasms
Drug Therapy
Intercalating Agents
Clinical Trials
Breast Neoplasms
Mutation
Survival
DNA
Therapeutics
Research

Keywords

  • Drug therapy
  • Genes, BRCA2
  • Mitomycin
  • Pancreatic neoplasms

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. / Chalasani, Pavani; Kurtin, Sandra; Dragovich, Tomislav.

In: Journal of the Pancreas, Vol. 9, No. 3, 05.2008, p. 305-308.

Research output: Contribution to journalArticle

@article{c95b52b2d3334796b3000ee336c63f38,
title = "Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation",
abstract = "Context: Gemcitabine remains the mainstay of palliative chemotherapy for those patients with unresectable or metastatic pancreatic cancer. Objective radiological responses to gemcitabine are rare and reported median survival is only about six months. New therapeutic concepts and strategies are needed in order to improve those dismal statistics. Case report: We report here a case of a patient with metastatic pancreatic cancer responding to a third-line therapy with combination of mitomycin C and capecitabine. Interestingly, the patient had a strong family history of breast cancer and tested positive to germline BRCA2 mutation. Conclusion: We feel that this is of interest because of preclinical reports of increased sensitivity of pancreatic cells carrying BRCA2 mutations to DNA-intercalating agents such as mitomycin C. Further research and clinical trials are warranted to support this novel concept.",
keywords = "Drug therapy, Genes, BRCA2, Mitomycin, Pancreatic neoplasms",
author = "Pavani Chalasani and Sandra Kurtin and Tomislav Dragovich",
year = "2008",
month = "5",
language = "English (US)",
volume = "9",
pages = "305--308",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "3",

}

TY - JOUR

T1 - Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation

AU - Chalasani, Pavani

AU - Kurtin, Sandra

AU - Dragovich, Tomislav

PY - 2008/5

Y1 - 2008/5

N2 - Context: Gemcitabine remains the mainstay of palliative chemotherapy for those patients with unresectable or metastatic pancreatic cancer. Objective radiological responses to gemcitabine are rare and reported median survival is only about six months. New therapeutic concepts and strategies are needed in order to improve those dismal statistics. Case report: We report here a case of a patient with metastatic pancreatic cancer responding to a third-line therapy with combination of mitomycin C and capecitabine. Interestingly, the patient had a strong family history of breast cancer and tested positive to germline BRCA2 mutation. Conclusion: We feel that this is of interest because of preclinical reports of increased sensitivity of pancreatic cells carrying BRCA2 mutations to DNA-intercalating agents such as mitomycin C. Further research and clinical trials are warranted to support this novel concept.

AB - Context: Gemcitabine remains the mainstay of palliative chemotherapy for those patients with unresectable or metastatic pancreatic cancer. Objective radiological responses to gemcitabine are rare and reported median survival is only about six months. New therapeutic concepts and strategies are needed in order to improve those dismal statistics. Case report: We report here a case of a patient with metastatic pancreatic cancer responding to a third-line therapy with combination of mitomycin C and capecitabine. Interestingly, the patient had a strong family history of breast cancer and tested positive to germline BRCA2 mutation. Conclusion: We feel that this is of interest because of preclinical reports of increased sensitivity of pancreatic cells carrying BRCA2 mutations to DNA-intercalating agents such as mitomycin C. Further research and clinical trials are warranted to support this novel concept.

KW - Drug therapy

KW - Genes, BRCA2

KW - Mitomycin

KW - Pancreatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=45749088199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749088199&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 305

EP - 308

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 3

ER -